The study by Sulli et al. showed the specific targeting of crucial cancer pathways especially autophagy and de-novo fatty acid synthesis by REV-ERB and CRY agonists, but it remains to be seen if similar effects will be observed in patient-derived systems52. Here, CRYL1 is linked to cancer.